Anavex Life Sciences Corp (AVXL)

[falconer66a]

A Journal Article Will Impress Equity Buyers

I don't think peer review articles of the individual trial results are important to the agencies.

But how might equity investors respond to the publication in a recognized medical journal where the safety and efficacy of blarcamesine against Alzheimer's is thoroughly authenticated? The authors tell that, with statistical significance, with no obviating side effects, the vast majority of Alzheimer's patients who took blarcamesine had their symptoms improve, were suppressed or stopped?

For me, when I see that journal article, I'll be buying a few more AVXLs. So will a lot of others. The share price will start to ascend, steeply.